In August, our scientific advisory board reviewed the totality of our data. We were very pleased to hear that they agree with our conclusion that these data support not only sarcopenia, but create multiple options in other muscle related and non-muscle related disorders. Based on their feedback we adjusted our funding strategy to optimize the clinical trajectory. We are very greatfull for their insigths! Our thank you goes to Prof MD PhD Johan Auwerx, Prof MD PhD Eric Verdin, Prof MD PhD Marco Sandri, Prof PhD Björn Schumacher, Prof PhD Bart Braeckman and Prof MD PhD Andrea Maier.